These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25027546)

  • 1. Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach.
    Gandjour A; Müller D
    Appl Health Econ Health Policy; 2014 Oct; 12(5):471-6. PubMed ID: 25027546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis.
    van Baal P; Meltzer D; Brouwer W
    Health Econ; 2016 Feb; 25(2):237-48. PubMed ID: 25533778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?
    Rappange DR; van Baal PH; van Exel NJ; Feenstra TL; Rutten FF; Brouwer WB
    Pharmacoeconomics; 2008; 26(10):815-30. PubMed ID: 18793030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio.
    van Baal PH; Feenstra TL; Hoogenveen RT; de Wit GA; Brouwer WB
    Health Econ; 2007 Apr; 16(4):421-33. PubMed ID: 17039573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation and the postponement of health care costs.
    van Baal PH; Feenstra TL; Polder JJ; Hoogenveen RT; Brouwer WB
    Health Econ; 2011 Apr; 20(4):432-45. PubMed ID: 21210494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The QALY approach - potentials and limits].
    Tunder R; Martschinke B
    Urologe A; 2014 Jan; 53(1):7-14. PubMed ID: 24362633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future unrelated medical costs need to be considered in cost effectiveness analysis.
    van Baal P; Morton A; Meltzer D; Brouwer W
    Eur J Health Econ; 2019 Feb; 20(1):1-5. PubMed ID: 29671143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous patient responses and the consistency principle in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Med Decis Making; 2012; 32(3):488-97. PubMed ID: 22101019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging diseases--do they prevent preventive health care from saving costs?
    Gandjour A
    Health Econ; 2009 Mar; 18(3):355-62. PubMed ID: 18833543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
    Hoerger TJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethical and value issues in insurance coverage for cancer treatment.
    Brock DW
    Oncologist; 2010; 15 Suppl 1():36-42. PubMed ID: 20237216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health care expenditures from living longer--how much do they matter.
    Gandjour A
    Int J Health Plann Manage; 2014; 29(1):43-51. PubMed ID: 23418021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward a broader view of values in cost-effectiveness analysis of health.
    Menzel P; Gold MR; Nord E; Pinto-Prades JL; Richardson J; Ubel P
    Hastings Cent Rep; 1999; 29(3):7-15. PubMed ID: 10420299
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.
    Ercolani G; Cucchetti A; Cescon M; Peri E; Brandi G; Del Gaudio M; Ravaioli M; Zanello M; Pinna AD
    Eur J Cancer; 2011 Oct; 47(15):2291-8. PubMed ID: 21652204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysis.
    Giorda CB; Nicolucci A; Pellegrini F; Kristiansen CK; Hunt B; Valentine WJ; Vespasiani G
    Diabet Med; 2014 May; 31(5):615-23. PubMed ID: 24246087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
    Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
    Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology.
    Olchanski N; Zhong Y; Cohen JT; Saret C; Bala M; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):931-40. PubMed ID: 26478989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.
    Manns B; Meltzer D; Taub K; Donaldson C
    Health Econ; 2003 Nov; 12(11):949-58. PubMed ID: 14601157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.